Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
Status:
Terminated
Trial end date:
2020-08-04
Target enrollment:
Participant gender:
Summary
This is a 24-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled,
parallel group, phase 3 study designed to evaluate if the safety and efficacy of
dapagliflozin 5 mg or 10 mg added to saxagliptin 5 mg plus metformin is superior to placebo
added to saxagliptin 5 mg plus metformin in reducing hemoglobin A1c (HbA1c).